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Abstract
Background: Activating mutations in the Transient Receptor Potential channel C6 (TRPC6) cause autosomal dominant focal
segmental glomerular sclerosis (FSGS). TRPC6 expression is upregulated in renal biopsies of patients with idiopathic
membranous glomerulopathy (iMN) and animal models thereof. In iMN, disease progression is characterized by
glomerulosclerosis. In addition, a context-dependent TRPC6 overexpression was recently suggested in complement-
mediated podocyte injury in e.g. iMN. Hence, we hypothesized that genetic variants in TRPC6 might affect susceptibility to
development or progression of iMN.
Methods & Results: Genomic DNA was isolated from blood samples of 101 iMN patients and 292 controls. By direct
sequencing of the entire TRPC6 gene, 13 single nucleotide polymorphisms (SNPs) were identified in the iMN cohort, two of
which were causing an amino acid substitution (rs3802829; Pro15Ser and rs36111323, Ala404Val). No statistically significant
differences in genotypes or allele frequencies between patients and controls were observed. Clinical outcome in patients
was determined (remission n = 26, renal failure n = 46, persistent proteinuria n = 29, follow-up median 80 months {range 51–
166}). The 13 identified SNPs showed no association with remission or renal failure. There were no differences in genotypes
or allele frequencies between patients in remission and progressors.
Conclusions: Our data suggest that TRPC6 polymorphisms do not affect susceptibility to iMN, or clinical outcome in iMN.
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Introduction
Membranous nephropathy (MN) is the leading cause of
nephrotic syndrome in the adult Caucasian population and is
characterized by immune complex deposition in the subepithelial
layer of the glomerular basement membrane. In one third of
patients, MN is caused by an underlying disease such as a
malignancy, infection or a systemic disease. Until recently, no
underlying cause could be identified in two thirds of patients and,
therefore, the disease was considered to be idiopathic (iMN) in
these patients. [1] In 2009 Beck et al. discovered antibodies against
the M-type phospholipase A2 receptor (PLA2R), a membrane
glycoprotein located on the podocyte, in patients with iMN. [2]
Further studies showed that antibodies against PLA2R are present
in approximately 70% of Caucasian patients with active disease.
[3,4] This finding thus provided evidence that iMN is an auto-
immune disease.
A recent genome-wide association study showed that genetic
variants in HLA-DQA1 and phospholipase A2 receptor (PLA2R1) were
most significantly associated with biopsy-proven iMN. [5]
Association with HLA regions has been identified in many
autoimmune diseases, the association with the PLA2R1 gene
supports the key role of the anti-PLA2R antibodies in the
pathogenesis of the disease. In an additional study we assessed if
rare genetic variants within the coding region of the PLA2R1 gene
could explain antibody formation. Although sequencing of the
complete coding sequence of PLA2R1 in 95 patients with iMN
confirmed associations of common single nucleotide polymor-
phisms (SNPs) with iMN, rare variants were present in only a
minority of patients (9%). [6] This data questions why iMN is rare,
as these SNPs occur frequently in the general population. It could
be hypothesized that a rare combination of (relatively) common
events (genetic variants and/or environmental factors) might
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constitute the pathogenetic trigger. In addition to HLA and
PLA2R1, variants in other genes might be involved.
One of the biggest unresolved issues in patients with iMN is the
highly variable disease course. Spontaneous remission occurs in
about 40–50% of patients, but another 30–50% of patients
progresses to end stage renal disease within 10 years. [7] Although
several predictive strategies have been proposed, it remains
difficult to identify patients with a high risk of disease progression.
[8,9] Progression of disease is accompanied by glomerulsclerosis in
renal biopsies. [10]
The Transient Receptor Potential channel C6 (TRPC6) is an
ion channel that is expressed in podocytes at the slit diaphragm
{Figure 1}. [11] This complex of interconnected proteins provides
both physical linkage as well as a signaling platform that regulates
podocyte behavior and architecture, and thereby affects glomer-
ular permeability. TRPC6 was recognized as an important slit
diaphragm component after TRPC6 gain-of-function mutations
were shown to be responsible for autosomal dominant focal
segmental glomerulosclerosis (FSGS), a leading cause of steroid-
resistant nephrotic syndrome that can rapidly progress to end-
stage renal disease (ESRD). [11–15] Animal studies show that
podocyte-specific transgenic TRPC6 overexpression leads to
albuminuria and histological findings similar to human FSGS.
[14,16] However, glomerular TRPC6 expression is also increased
in acquired human proteinuric diseases. Importantly, this occurs in
human MN, as well as in the passive Heymann nephritis animal
model for MN. [13,17] Furthermore, angiotensin II (AngII)
activates specific TRPC6-mediated intracellular pathways in the
podocyte. [17–20] Angiotensin receptor blockers, angiotensin
converting enzyme inhibitors and calcineurin inhibitors, all three
utilized to treat proteinuria in MN, were shown to inhibit these
TRPC6-mediated cascades. [17,19] Thus, TRPC6 is not only
primarily involved in the pathogenesis of FSGS, but could also
mediate podocyte damage and/or progression to ESRD in other
proteinuric diseases like MN. Therefore, we hypothesized that
sequence variations in the TRPC6 gene could affect susceptibility
to development and/or progression of iMN.
In the present study, we screened a cohort of 101 biopsy-proven
iMN patients for TRPC6 sequence variations by direct sequencing
of all 13 exons of the TRPC6 gene. Furthermore, we assessed
whether genetic variants were associated with disease progression
and outcome in patients with iMN.
Subjects and Methods
Patients
The present study included iMN patients referred to our centre
between 1995 and 2007. In all patients, the diagnosis of iMN was
established by renal biopsy and secondary causes were excluded
according to local routine clinical work up. [21] Baseline data on
age, sex and ethnicity were present for all patients. To allow
subgroup analysis of anti-PLA2R positive patients, the presence of
anti-PLA2R antibodies in the serum was evaluated. Serum
samples at diagnosis were available for most patients. The assay
for measuring anti-PLA2R antibodies has been previously
described. [22]
iMN patients were evaluated using a standardized protocol as
previously described. [23] Patients were prospectively followed,
and data on treatment and outcome (e.g. remission and renal
survival) are obtained. For the current study we evaluated the
occurrence of spontaneous remissions and/or renal failure.
Spontaneous remission was defined as proteinuria ,2.0 g/day
with stable renal function in a patient not treated with
immunosuppressive agents. Renal failure/progression was defined
as an increase in serum creatinine .25% from baseline with a
serum creatinine .135 mmol/l or an increase .50% from
baseline.
Ethics statement
The study was approved by the ethics committee of the
Radboud university medical center (Commissie Mensgebonden
Onderzoek (CMO) Regio Arnhem Nijmegen, nr.9701-0016). All
patients gave written informed consent prior to participation in the
study.
Sequencing
DNA was purified from blood samples using salt extraction
according to a previously described protocol. [24] All exons
including splice sites in the TRPC6 gene were sequenced. Sense
and antisense primers were designed using Primer3. [25] PCR
primers and conditions are given in Table 1. PCR products were
purified using Multiscreen filter plates (Millipore Carrigtwohill,
Cork, Ireland). Purified products were used for Sanger sequence
analysis (bidirectional) with dye-termination chemistry (BigDye
Terminator, version 3) on a 3730 DNA analyzer (Applied
Biosystems, Inc., Foster City, CA, USA).
Analysis
TRPC6 sequences were analyzed for the presence of genetic
variants in comparison with the published reference sequence for
human TRPC6 (mRNA NM_004621.5). Ethnically matched
population allele frequencies of the identified variants were
obtained from the 1000 Genomes project (1000 Genomes release
10 - March 2012). [26] Variants were considered to be common
(previously reported with allele frequency .1%), rare (previously
reported with allele frequency ,1%), or novel (not previously
reported in the 1000 Genome project nor in dbSNP 136).
SNP genotyping. SNPs that lead to amino acid substitutions,
and/or that were rare (previously with allele frequency ,1%),
completed with SNPs that had a the minor allele frequency in the
patient cohort of .10%, were selected for genotyping in 292
healthy individuals from the same geographical region (Table 2).
Genotyping was performed using Taqman allelic discrimination
assays (Invitrogen, Bleiswijk, The Netherlands) according to the
instructions of the manufacturer. The fluorescent signal for allelic
discrimination was determined after amplification using an end-
point reading on the 7500 Fast Real-time System (Applied
Biosystems). Automated allele calling was performed by allelic
discrimination plots using SDS 1.4 software (Applied Biosystems).
We included 5% duplicate samples in each plate as quality control.
Association analysis. Frequencies of SNPs identified in iMN
patients were compared with genotype data of 379 Caucasian
controls that were downloaded from the 1000 Genomes project
(release 10). In an attempt to increase power, data of 292 healthy
controls were added for variants in 5 SNPs, as detected with
Taqman assay. Association analyses were performed using the
whole genome analysis toolset PLINK (version 1.07). [27]
Significance was set a p,0.05. SNPs with an allele frequency of
0.1 and higher were used to construct haplotypes. Haplotype
analysis was also performed using PLINK. Next, frequencies of
SNPs identified in patients with progressive disease (renal failure)
were compared with frequencies observed in patients with a
spontaneous remission of proteinuria as described above.
Power calculations. In order to be able to estimate the effect
size of the genetic variants, we performed a genetic power
calculation using the online Harvard Genetic Power Calculator
(http://pngu.mgh.harvard.edu/,purcell/gpc/). We calculated
the effect size that could be excluded with 80% power and a
SNPs in TRPC6 and iMN
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two-sided p-value of 0.05, for various frequencies of the high-risk
allele (ranging from 0.200 to 0.008).
Results
Patient characteristics
A total of 101 patients with biopsy proven iMN were included in
the present study. Patients were mostly male (77%) and mean age
at diagnosis was 51615 years. All patients were of self-reported
Caucasian ancestry. Serum samples at onset of disease were
available for 92 patients, anti-PLA2R antibodies were present in
62 samples (67%).
Sequencing
In 101 patients with iMN we identified eight sequence variants
in the coding region of the TRPC6 gene (Table 2). Of the eight
coding variants observed, six were common SNPs and two were
rare (See Methods for definitions). These rare variants (c.888G.A
and c.2142G.T) were both encountered once in two different
patients in a heterozygous state, but did not result in amino acid
changes (synonymous mutations). Only two of the common SNPs
resulted in an amino acid substitution (rs3802829; Pro15Ser and
rs36111323, Ala404Val). Four additional common SNPs were
observed in the intron regions, as well as one rare variant in the 59-
UTR (c1-10 C.A). The latter was present in 5 patients, all in a
heterozygous state.
Association between TRPC6 variants and occurrence of
iMN
Control data were obtained from the 1000 Genomes project as
described. To increase power to detect possible genotype
frequency differences between our iMN cohort and the general
population, 292 healthy Caucasian controls from the same
geographical area were included as an additional control group
for the frequency of five SNPs. These five SNPs were selected by
previously specified criteria. Association analysis showed that there
were no significant differences in the allele frequencies of both the
coding and non-coding SNPs between the 101 iMN patients and
ethnically matched controls (Table 2). Based on our power
calculations, the effect sizes that could be excluded for the various
frequencies of the high-risk allele were above 1.6 to 4. For the two
SNPs leading to amino acid substitutions in exons, these were 1.7
and 1.8, respectively.
When analyzing associations for the subgroup of PLA2R
positive patients (n = 62), the synonymous SNP rs12366144 was
more frequently present in patients than in controls (p = 0.02)
(Table 2). However, when correcting for the multiple testing of 12
SNPs, (p-value should be less than 0.05/12= 0.00417), this
significant association disappeared. Haplotype analysis was per-
formed including all available SNPs, but no significant associations
were determined.
Association between TRPC6 variants and clinical outcome
After a median follow-up of 80 months (range 15–166)
spontaneous remission had occurred in 26 patients, and 46
patients had progressed to renal failure. Of the remaining patients,
six had persistent proteinuria .2.0 gram/day with stable renal
Figure 1. TRPC6 topology. Structure of the TRPC6 monomer. TRPC6 belongs to the large family of TRP channels, which contain six
transmembrane domains, one pore-forming region and large intracellular N- and C-tails. Four subunits are required to assemble a functional channel.
In the pococyte, TRPC6 is part of the slit diaphragm multiprotein complex. TRP: transient receptor potential, ANK: Ankyrin repeat, cc: coiled–coiled
domain, CIRB: CaM/IP3R-binding domain.
doi:10.1371/journal.pone.0102065.g001
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function, 19 patients were censored for outcome analysis because
of treatment with immunosuppressive agents, and four patients
were lost to follow-up. None of the 13 identified TRPC6 sequence
variations correlated with remission or renal failure (Table 3). An
additional analysis comparing those patients in whom spontaneous
remission occurred (n = 26) to all others (n = 75) also did not show
differences between groups (data not shown).
Discussion
In this study, 13 SNPs in the gene encoding TRPC6 were
identified in our cohort of 101 biopsy-proven iMN patients. None
of the identified SNPs was associated with the occurrence of iMN
per se. In addition, the presence of TRPC6 SNPs was not associated
with clinical outcome in terms of remission rate, persistence of
proteinuria or progression to renal failure. Thus, our data do not
confirm the hypothesis that TRPC6 SNPs could confer suscepti-
bility to, or alter the clinical course in iMN.
Pathogenesis of iMN has been an unsolved mystery for decades.
The histological features of MN were first described in 1957. [28]
The characteristic finding in kidney biopsies of subepithelial
deposits that consisted of IgG and complement pointed to an
immunological disease ontology. In a rat model of MN,
Heymann’s nephritis, the disease is caused by IgG antibodies
targeting megalin, a protein expressed by both rat tubular cells and
podocytes. [29] Since megalin is not present on human podocytes,
other pathophysiological mechanisms and other antigenic targets
have been considered. A major breakthrough came with the
discovery by Beck et al. of circulating auto-antibodies against the
M-type Phospholipase A2 receptor (PLA2R), a protein expressed
by human podocytes, in the majority of patients with iMN. [2]
Anti-PLA2R antibodies in iMN are mainly of the IgG4 subclass,
both in serum and in biopsies. IgG4 is considered not to activate
complement, but immune deposits in iMN contain large amount
of complement C3. It has been suggested that anti-PLA2R
antibodies might activate the lectin pathway of the complement
cascade by binding to Mannose Binding Lectin. [30] However, the
mechanism by which the antibodies finally lead to the membra-
nous phenotype with severe podocyte damage is still unknown.
Furthermore, the trigger for autoantibody formation remains
unclear. A rare combination of (relatively) common events (genetic
variants and/or environmental factors) might serve as a pathoge-
netic trigger in a multi-hit setting.
Next to these remaining questions on pathogenetic issues, the
substantial interindividual variability in the course and prognosis
of the iMN is also unexplained as yet. Why is the disease benign
with a single episode and spontaneous remission in some patients,
and do other patients progress to ESRD after several treatment
resistant episodes? The genetic profile of the patient may be one of
the aspects contributing to this interindividual variability. In
another glomerulopathy, IgA nephropathy, common polymor-
phisms in several genes (MYH, TLR9) were associated with disease
progression and development of ESRD. [31,32] Since TRPC6
gain-of-function mutations cause podocyte injury leading to
hereditary FSGS, glomerular TRPC6 expression is increased in
MN, and glomerulosclerosis occurs in progressive MN, we
hypothesized that polymorphisms in TRPC6, contribute to the
susceptibility to develop iMN and/or progress to end-stage renal
disease. Of note, Chen et al. previously showed that three TRPC6
SNPs, which they selected on reasons that were not clearly
defined, did not correlate with the occurrence of MN. [33] In our
study, all exons were sequenced including splice sites in the TRPC6
gene to identify polymorphisms in the coding regions of TRPC6 in
an unbiased manner. While we identified TRPC6 SNPs in iMN
patients, we found no association of these SNPs with disease
occurrence or progression, although based on the number of
patients in our cohort a limited effect size could have been missed.
This means that the alleles we identified could still have functional
effects on TRPC6 channel activity, of which the resulting clinical
effect would fall under the effect size we can rule out. However,
the majority of the identified SNPs [11] were either intronic or
synonomous, minimizing the chance of any functional relevance.
The two SNPs causing predicted amino acid substitutions,
although of interest, clearly did not contribute to the development
of MN in all patients.
In the PLA2R positive patients, one SNP showed an association,
but the statistical significance of this association was lost after
correction for multiple testing. In terms of genetic association
studies, our cohort is quite small and we, therefore, cannot exclude
that our study is underpowered to find existing associations,
especially with regard to haplotypes. As only the coding regions of
the TRPC6 gene were sequenced, information on intronic
polymorphisms and/or SNPs in the promoter region of the gene
that might influence expression of the TRPC6 protein, is lacking.
Table 1. Primers used to sequence the 13 exons of TRPC6.
Exon F/R primer Primer sequence 59—39
1 F primer GTCTGCCCAGGTCCAGTTC
1 R primer GTACACACGCGGGTTCAG
2_01 F primer GATGAATGGCAAGTCATTTGG
2_01 R primer AACCTCTTGCCTTCAGCAAA
2_02 F primer GCCAATGAGCATCTGGAAAT
2_02 R primer AGCCGTCATGACTGGATCTT
2_03 F primer GATTGAACGGCCTCATGATT
2_03 R primer GGTAGCGATCACAACTTTTGC
3 F primer AACGTGGTATTCTCCATTATTGC
3 R primer AGCACCAACAAGAACCAAAA
4 F primer GCCATTTGTTTGTTGCCTGT
4 R primer TGGAGATAAGATTTTTCCCCACT
5 F primer GGAGATCATTGGAATGTGCAG
5 R primer AATGAACCCAAGGCAACTGT
6 F primer TTGGGACCAAATTTTGAAGG
6 R primer GAGAATTGTGCAGTAACCGAACT
7 F primer GGAGACTTCCATTCGAAAACC
7 R primer CCAAAACATTATCCCATGGAC
8 F primer TCACTAATTTGCAGACACTAAACAA
8 R primer CGAAGAGCAGTCCATGCTT
9 F primer CGATCACTGGGGTCTGAGAG
9 R primer AAAGGGATGTGGCATAGTGG
10 F primer AGGGAAGAACCCCGTAAGAA
10 R primer GCTTCTGAACATCTGTCCCTTT
11 F primer TTGGCAGCCACAAAGTCTAA
11 R primer AAGAATCACATAGTTCAAGAACCTAAA
12 F primer GGCTCACTACAGGGAGGAAG
12 R primer GCTCTCCAGGCACTCTGC
13 F primer TTTCCTCCTGTCCCACAGTC
13 R primer GGCTCCAGATGATAGGATGG
F, forward; R, reverse.
doi:10.1371/journal.pone.0102065.t001
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Since it is TRPC6 gain-of-function that is associated with podocyte
injury, transcriptionally-mediated increased or diminished TRPC6
expression as a result of genetic variants in TRPC6 regulatory
regions, might influence susceptibility and prognosis.
However, assuming that TRPC6 SNPs do not affect occurrence
and progression in iMN, the question still remains why TRPC6 is
overexpressed in iMN. Since TRPC6 is overexpressed in several
human glomerular diseases and animal models of podocyte injury
and glomerular disease, it could be a common effector in the
resulting podocyte injury.[13,17] We have previously shown that
AngII-mediated activation of the deleterious calcineurin/NFAT
pathway, which includes Ca2+ influx through TRPC6 itself, leads
to enhanced transcriptional expression of TRPC6 in the podocyte.
[17] In addition, antiproteinuric agents like angiotensin receptor
blockers, angiotensin converting enzyme inhibitors, calcineurin
inhibitors and vitamin D normalize TRPC6 expression in
podocyte injury and experimental glomerular disease. [17,34]
Alternatively, an interesting hypothesis could be that e.g. anti-
PLA2R antibodies actually activate PLA2R on the surface of the
podocyte. In cell types other than podocytes, Ca2+ influx was
demonstrated to be coupled to PLA2R activation. [35] Hypothet-
ically, binding of anti-PLA2R antibodies to PLA2R on the
podocyte could activate Ca2+ influx through TRPC6 and/or
increase TRPC6 expression. A recent study from Kistler et
al.,suggests that increasing TRPC6 expression might at first
actually serve to protect the podocyte from complement-mediated
injury, which seems crucial in MN. [36] Eventually, prolonged
TRPC6 overexpression might then become deleterious. While
TRPC6 SNPs do not appear to alter susceptibility to iMN
occurrence and progression, this new hypothesis suggests that
TRPC6 indeed plays a pathophysiological role in iMN.
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Table 3. Genotypes in iMN patients with clinical remission versus patients with renal failure.
Genotype Remission n=26 (%) Renal Failure n=46 (%) p-value*
rs191383391 CC 25 (96.2) 43 (93.5) 0.64
CA 1 (3.8) 3 (6.5)
rs3802829 CC 22 (84.6) 37 (80.4) 0.68
CT 4 (15.4) 9 (19.6)
rs17096918 GG 23 (88.5) 37 (80.4) 0.40
GA 3 (11.5) 9 (19.6)
rs10501986 AA 9 (34.6) 10 (21.7) 0.09
AG 15 (57.7) 25 (54.3)
GG 2 (7.7) 11 (23.9)
rs144891994 GG 26 (100) 46 (100) 1.00
rs4542378 CC 9 (34.6) 9 (19.6) 0.09
CT 15 (57.7) 27 (58.7)
TT 2 (7.7) 10 (21.7)
rs36111323* GG 19 (73.1) 31 (67.4) 0.74
GA 7 (26.9) 14 (30.4)
rs61743044 CC 26 (100) 43 (93.5) 1.00
CT 0 (0) 3 (6.5)
rs12366144 TT 16 (61.5) 20 (43.5) 0.18
TC 9 (34.6) 23 (50.0)
CC 1 (3.8) 3 (6.5)
rs145077205 GG 25 (96.2) 46 (100) 0.18
GT 1 (3.8) 0 (0)
rs7105083 CC 15 (57.7) 26 (56.5) 0.91
CT 10 (38.5) 18 (39.1)
TT 1 (3.8) 2 (4.3)
rs72984209 CC 23 (88.5) 41 (89.1) 0.93
CT 3 (11.5) 5 (10.9)
rs12805398 GG 18 (69.2) 32 (69.6) 0.88
GA 8 (30.8) 14 (30.4)
*N= 45 for renal failure.
*P-value for minor allele frequencies-comparison (Mann-Whitney U).
doi:10.1371/journal.pone.0102065.t003
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